Measure Description
Percentage of patients aged 18 years and older, who report benign paroxysmal positional vertigo (BPPV)-related symptoms and are screened with a dizziness assessment questionnaire and undergo positional nystagmus testing AND, if diagnosed or identified with BPPV, received a BPPV-related care plan and vestibular intervention(s) or treatment(s) AND who have an improvement in nystagmus or report an improvement in BPPV-related symptoms, and report a meaningful clinically important difference (MCID) improvement of BPPV-related quality of life (QoL).
Denominator
Denominator Criteria (Eligible cases):
Strata 1: Patients aged 18 years and older with a patient encounter
Strata 2: Patients aged 18 years and older who are screened with a dizziness assessment questionnaire, undergo positional nystagmus testing, and are identified or diagnosed with BPPV
Strata 3: Patients aged 18 years and older who received a BPPV-related care plan and vestibular intervention(s) or treatment(s)
Numerator
The number of patients in the denominator who demonstrated a response to treatment, using the identified validated PTSD self-report symptom monitor for the patient’s age group with a demonstrated change score indicating improvement.
1. For adults (age 18 and older), the instrument is the PCL-5, and a score reflecting symptom improvement is decrease of 5 or more on the total score from baseline administration.
2.For children and adolescents, age 7-17, a CATS, score decrease of 12 or more in the total score OR a score